HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $81
Author: Benzinga Newsdesk | November 05, 2025 06:32am
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $80 to $81.